GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
WO1993003769A1
(en)
|
1991-08-20 |
1993-03-04 |
THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
DK0605522T3
(da)
|
1991-09-23 |
2000-01-17 |
Medical Res Council |
Fremgangsmåde til fremstilling af humaniserede antistoffer
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
WO1994012649A2
(en)
|
1992-12-03 |
1994-06-09 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
DE614989T1
(de)
|
1993-02-17 |
1995-09-28 |
Morphosys Proteinoptimierung |
Verfahren für in vivo Selektion von Ligandenbindende Proteine.
|
WO1995000655A1
(en)
|
1993-06-24 |
1995-01-05 |
Mc Master University |
Adenovirus vectors for gene therapy
|
DE69429816T2
(de)
|
1993-09-01 |
2002-09-19 |
Sanquin Bloedvoorziening |
C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
|
EP1637608B1
(en)
|
1993-10-25 |
2009-07-22 |
CANJI, Inc. |
Recombinant adenoviral vector and methods of use
|
SG119177A1
(en)
|
1994-12-09 |
2006-02-28 |
Imp College Innovations Ltd |
Identification of genes
|
US6969601B2
(en)
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
AU3998400A
(en)
|
1999-02-09 |
2000-08-29 |
3-Dimensional Pharmaceuticals, Inc. |
Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
|
AU4369000A
(en)
|
1999-04-26 |
2000-11-10 |
Duke University |
Inhibition of complement action
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
JP2003521914A
(ja)
|
2000-01-31 |
2003-07-22 |
ファーミング インテレクチュアル プロパティー ベー.フェー. |
トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター
|
AU2001249410A1
(en)
|
2000-03-23 |
2001-10-03 |
Tanox, Inc. |
Anti-c2/c2a inhibitors of complement activation
|
US7071299B2
(en)
|
2000-06-21 |
2006-07-04 |
Zymogenetics, Inc. |
Peptide and polypeptide inhibitors of complement C1s
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
CA2454562A1
(en)
|
2001-07-26 |
2003-02-06 |
Alexion Pharmaceuticals, Inc. |
Method of improving cognitive function
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
EP1545611B1
(en)
|
2002-09-06 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
CA2524534C
(en)
|
2003-05-15 |
2012-12-11 |
Sek Chung Fung |
Methods and compositions for the prevention and treatment of sepsis
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
US20080075712A1
(en)
|
2003-10-14 |
2008-03-27 |
Kunihiro Hattori |
Double Specific Antibodies Substituting For Functional Proteins
|
JP2007512846A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
KR100891620B1
(ko)
|
2004-04-13 |
2009-04-02 |
에프. 호프만-라 로슈 아게 |
항-p-셀렉틴 항체
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US20060018896A1
(en)
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
EP2382991A1
(en)
|
2004-06-10 |
2011-11-02 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
AU2005313971B2
(en)
|
2004-12-08 |
2011-10-13 |
Immunomedics, Inc. |
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
|
KR20080002832A
(ko)
|
2005-03-16 |
2008-01-04 |
얀센 파마슈티카 엔.브이. |
보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
|
EP2529746A1
(en)
|
2005-06-06 |
2012-12-05 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of reperfusion injury
|
US20070093443A1
(en)
|
2005-10-21 |
2007-04-26 |
Madison Edwin L |
Modified proteases that inhibit complement activation
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
WO2007070375A2
(en)
|
2005-12-09 |
2007-06-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
AU2006327989B2
(en)
|
2005-12-21 |
2012-06-07 |
Pharming Intellectual Property Bv |
Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
|
FR2897868B1
(fr)
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
US20090269356A1
(en)
|
2006-03-08 |
2009-10-29 |
David Epstein |
Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
|
CA2662480C
(en)
|
2006-09-05 |
2016-11-08 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
LT3028716T
(lt)
|
2006-10-10 |
2020-12-10 |
Regenesance B.V. |
Komplemento slopinimas nervų regeneracijos pagerinimui
|
WO2008074227A1
(en)
|
2006-12-19 |
2008-06-26 |
Versitech Limited |
Synthetic ion channels
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
ATE543835T1
(de)
|
2007-07-16 |
2012-02-15 |
Genentech Inc |
Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
|
WO2009035786A1
(en)
|
2007-08-03 |
2009-03-19 |
Genentech, Inc. |
Humanized anti-fgf19 antagonists and methods using same
|
US20110190221A1
(en)
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
AU2009239437B2
(en)
|
2008-04-25 |
2014-11-13 |
University Of Washington |
Levels of BCMA protein expression on B cells and use in diagnostic methods
|
US20090324585A1
(en)
|
2008-06-12 |
2009-12-31 |
The Trustees of the Leland Standford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
AU2009313203B2
(en)
|
2008-11-10 |
2015-08-27 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
BRPI0923199B8
(pt)
|
2008-12-01 |
2021-07-27 |
Univ Leland Stanford Junior |
método para determinar a presença de anticorpos de fixação de complemento
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
CN102597005A
(zh)
|
2009-06-23 |
2012-07-18 |
阿雷克森制药公司 |
与补体蛋白质结合的双特异性抗体
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
PT2488203T
(pt)
|
2009-10-16 |
2017-03-10 |
Univ Leicester |
Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
|
WO2011102342A1
(ja)
|
2010-02-16 |
2011-08-25 |
国立大学法人京都工芸繊維大学 |
抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
|
US8999340B2
(en)
|
2010-03-01 |
2015-04-07 |
Alexion Pharmaceuticals, Inc. |
Methods for treating multiorgan, systemic degos' disease with a complement inhibitor
|
AU2011245117B2
(en)
|
2010-04-30 |
2015-03-12 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for using the antibodies
|
CN103003697A
(zh)
|
2010-05-17 |
2013-03-27 |
得克萨斯系统大学董事会 |
来自动物的单克隆抗体的快速分离
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
UY33578A
(es)
|
2010-08-31 |
2012-03-30 |
Sanofi Sa |
PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
PL3156420T3
(pl)
|
2010-12-06 |
2019-08-30 |
Seattle Genetics, Inc. |
Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
|
JP5937197B2
(ja)
|
2011-04-08 |
2016-06-22 |
ユニバーシティー オブ レスター |
Masp−2依存性補体活性化に関連した状態を治療するための方法
|
DK2704743T3
(en)
|
2011-05-04 |
2020-05-25 |
Omeros Corp |
Compositions for inhibiting masp-2 dependent complement acitivation
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
CN104080474B
(zh)
|
2011-12-22 |
2016-04-27 |
德国杰特贝林生物制品有限公司 |
C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
|
JP6081699B2
(ja)
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Il−28bの分析方法
|
CA3124553A1
(en)
|
2012-10-25 |
2014-05-01 |
Bioverativ Usa Inc. |
Anti-complement c1s antibodies and uses thereof
|
CN104884088B
(zh)
|
2012-11-02 |
2018-06-15 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
RU2663349C2
(ru)
|
2013-01-31 |
2018-08-03 |
СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН |
Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
|
EP4252769A3
(en)
|
2013-07-09 |
2023-11-29 |
Annexon, Inc. |
Anti-complement factor c1q antibodies and uses thereof
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
SI3280440T1
(sl)
|
2015-04-06 |
2023-03-31 |
Bioverativ Usa Inc. |
Humanizirana protitelesa proti C1S in načini uporabe
|
BR112017027578A2
(pt)
|
2015-06-26 |
2018-08-28 |
Bioverativ Usa Inc |
métodos de tratamento de distúrbios autoimunes e aloimunes
|
JP7069138B2
(ja)
|
2016-10-12 |
2022-05-17 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
抗C1s抗体およびその使用方法
|
SG11201907583TA
(en)
|
2017-03-14 |
2019-09-27 |
Bioverativ Usa Inc |
Methods for treating complement-mediated diseases and disorders
|